Literature DB >> 23612851

Synthesis and in vitro cytotoxic evaluation of novel N-(3,4,5-trimethoxyphenyl)pyridin-2(1H)-one derivatives.

Taijie Chen1, Yu Luo, Li Sheng, Jia Li, Youhong Hu, Wei Lu.   

Abstract

A series of novel [Formula: see text]-(3,4,5-trimethoxyphenyl)pyridin-2([Formula: see text])-one derivatives were designed, synthesized, and evaluated for their in vitro cytotoxicity against human colon cancer cells HCT-116. The key steps involved consecutive Chan-Lam- and Buchwald-Hartwig couplings. Most of these C-6 substituted pyridone derivatives showed moderate antiproliferative activity. The preliminary SAR indicated that the conformationally restricted pyridones exhibited more potent cytotoxicity than the flexible counterparts. In addition, cell cycle analysis of the selected compounds 4b and e showed a G2/M arrest, suggesting a possible antitubulin mechanism for these novel pyridone derivatives.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23612851     DOI: 10.1007/s11030-013-9442-1

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  21 in total

1.  In vitro and in vivo biological evaluation of new 4,5-disubstituted 1,2,3-triazoles as cis-constrained analogs of combretastatin A4.

Authors:  Núria Mur Blanch; Guy G Chabot; Lionel Quentin; Daniel Scherman; Stéphane Bourg; Daniel Dauzonne
Journal:  Eur J Med Chem       Date:  2012-05-09       Impact factor: 6.514

2.  Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.

Authors:  Zhiliang Lv; Chunquan Sheng; Tiantian Wang; Yikai Zhang; Jia Liu; Jilu Feng; Hailing Sun; Hanyu Zhong; Chunjuan Niu; Ke Li
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

Review 3.  Recent development of cyclic amide (pyridone/lactam) moiety containing heterocycles as protein kinase inhibitors.

Authors:  Linyi Wei; Sanjay V Malhotra
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

4.  Insights into structure-activity relationships from lipophilicity profiles of pyridin-2(1H)-one analogs of the cardiotonic agent milrinone.

Authors:  Modesto de Candia; Paola Fossa; Saverio Cellamare; Luisa Mosti; Angelo Carotti; Cosimo Altomare
Journal:  Eur J Pharm Sci       Date:  2005-09       Impact factor: 4.384

Review 5.  Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.

Authors:  M Marrelli; F Conforti; G A Statti; X Cachet; S Michel; F Tillequin; F Menichini
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Synthesis and evaluation of novel 2-pyridone derivatives as inhibitors of phosphodiesterase3 (PDE3): a target for heart failure and platelet aggregation.

Authors:  Mettu Ravinder; Budde Mahendar; Saidulu Mattapally; Kommi Venkata Hamsini; Thatikonda Narendar Reddy; Chilappa Rohit; Kolupula Srinivas; Sanjay Kumar Banerjee; Vaidya Jayathirtha Rao
Journal:  Bioorg Med Chem Lett       Date:  2012-05-11       Impact factor: 2.823

7.  Combretastatin A-4 derivatives: synthesis and evaluation of 2,4,5-triaryl-1H-imidazoles as potential agents against H1299 (non-small cell lung cancer cell).

Authors:  Chih-Hua Tseng; Chi-Yi Li; Chien-Chih Chiu; Huei-Ting Hu; Chein-Hwa Han; Yeh-Long Chen; Cherng-Chyi Tzeng
Journal:  Mol Divers       Date:  2012-09-26       Impact factor: 2.943

Review 8.  Developments of combretastatin A-4 derivatives as anticancer agents.

Authors:  Y Shan; J Zhang; Z Liu; M Wang; Y Dong
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 9.  The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.

Authors:  Q Li; L A Mitscher; L L Shen
Journal:  Med Res Rev       Date:  2000-07       Impact factor: 12.944

Review 10.  Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches.

Authors:  Andreas G Tzakos; Demosthenes Fokas; Charlie Johannes; Vassilios Moussis; Eleftheria Hatzimichael; Evangelos Briasoulis
Journal:  Molecules       Date:  2011-05-27       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.